A continuación puedes consultar el detalle de las comunicaciones GETECCU presentada en ECCO 2026 divididas por tipo de comunicación:
DOP012. Fecal calprotectin predicts relapse in ulcerative proctitis: a 12-month prospective cohort study
Ferreiro-Iglesias et al.
DOP032. Comparative study on the effectiveness, durability, and safety of upadacitinib versus risankizumab after anti-TNF failure in Crohn’s Disease: The U-PARIS study of ENEIDA
Rubin de Célix et al.
DOP044. Prevalence and factors associated with inflammatory bowel disease (IBD) activity during pregnancy: updated data from the Dumbo registry.
Tomás et al.
DOP 125. Functional Validation of the ENEIDA–UR-CARE Synchronisation Using Quality-of-Care Queries
Burisch et al.
P0256. Quality of screening for human papillomavirus in women with inflammatory bowel disease (EII-VIP ENEIDA study)
Artero A et al.
P0282. Clinical and biological factors as predictors of mucosal healing in moderate ulcerative colitis treated with steroids
Mañosa et al.
P0287. Small bowel capsule endoscopy and ileocolonoscopy for activity grading in ileal Crohn’s disease, a comparative analysis. Results from the CAPITER study, a multicenter study from the Young GETECCU Group
Marqués-Camí et al.
P0716. Safety of biologic and small molecule therapies in IBD patients with previous cancer: risk of recurrence or new neoplasia
Calvo et al.
P0734. Quality of life and mucosal healing in Ulcerative Colitis: CAVI_CU prospective study by GETECCU
Alonso I et al.
P0779. Prevalence, clinical characterisation and therapeutic outcomes of non-fistulising perianal lesions in Crohn’s disease (ULCERS-CD): Results from the ENEIDA registry of GETECCU
Casanova MJ et al.
P0907. Short-term effectiveness and safety of Mirikizumab in ulcerative colitis: real-world evidence from the ENEIDA registry of GETECCU
Gutierrez A et al.
P0918. Reproductive outcomes after in vitro fertilisation in women with inflammatory bowel disease. Preliminary results of FIVEII study of young GETECCU group
Madero L, et al
P0958. Safety of ustekinumab vs anti-TNF, immunomodulators, or no immunosuppressive therapy during pregnancy in IBD: DUMBO Registry
Aranguren et al.
P1016. Impact of Multiple Sclerosis on the course of Inflammatory Bowel Disease: The MULTIPLEII case-control study from the Young Group of GETECCU
Roig et al.
P1097. Safety and effectiveness of advanced therapies in patients with Inflammatory Bowel Disease and compensated cirrhosis. Preliminary data from the HEP-IBD study. A study from the young group of GETECCU
E. Fuentes-Valenzuela et al
P1105. Switching to Subcutaneous Infliximab for Regaining Clinical Remission in Inflammatory Bowel Disease Patients who lost response to Intravenous Infliximab: An Observational Study from the ENEIDA Registry
E. Brunet et al
